Servier
Servier is a global pharmaceutical company specializing in oncology, immuno-inflammation, cardiovascular, metabolic diseases, and neuroscience, with a significant investment in R&D.
Global Operations of Servier
Servier operates in more than 150 countries, providing its pharmaceutical products and services on a worldwide scale. The company's extensive global presence allows it to supply essential medications and therapies to a vast population, driving its mission to make a difference in patient health globally.
Focus on Oncology and Immuno-Inflammation Therapies
Servier emphasizes the development of targeted therapies in oncology, aiming to provide effective treatment options for cancer patients. Additionally, the company is committed to advancing new therapies in the field of immuno-inflammation, seeking innovative solutions to manage these complex conditions.
Servier’s Open Innovation Initiatives
Servier collaborates with academic institutions, startups, pharmaceutical companies, and biotechnology partners through its open innovation initiatives. This collaborative approach facilitates the exchange of knowledge and resources, propelling the development of cutting-edge therapies and medical solutions.
Servier Paris-Saclay Research & Development Institute
The establishment of the Servier Paris-Saclay Research & Development Institute underlines the company's commitment to scientific innovation. This institute serves as a hub for research activities, fostering advancements in various therapeutic fields through state-of-the-art facilities and collaboration with external partners.
Commitment to Cardiovascular and Metabolic Diseases
For over 60 years, Servier has maintained a strong dedication to addressing cardiovascular and metabolic diseases. The company continues to invest in research and development to provide effective treatments for these prevalent conditions, reflecting its long-standing commitment to improving patient outcomes.